matt teague First MDL trial over testosterone replacement drugs set for JuneThousands of men have suffered negative and even life-threatening side effects after taking testosterone replacement drugs and they will soon have their day in court to question the drugs’ manufacturers. The first of eight bellwether cases in a multidistrict litigation (MDL) goes to trial in June.

Drug manufacturers have promised men with low testosterone or “Low T” that the hormone replacement drugs will reverse symptoms of the condition including low sex drive, fatigue, muscle loss and weight gain. However, many consumers allege they got more than they bargained for – to their detriment.

In 2014, a Food and Drug Administration (FDA) investigation confirmed findings from two studies linking the drugs to significantly higher risk of stroke, heart attack and death, Beasley Allen previously reported. It also found evidence that the drugs may cause dangerous blood clots in the legs, known as deep vein thrombosis, which can lead to pulmonary embolism. As a result, the FDA ordered drug manufacturers to update their safety labels to include a new warning for deep vein thrombosis blood clotting.

Later that year, according to Beasley Allen, the U.S. Judicial Panel on Multidistrict Litigation established the MDL for consumers seeking to hold drug manufacturers accountable for adverse side effects linked to testosterone replacement therapy. Righting Injustice recently reported the number of lawsuits has grown from 45 to 5,550 since the MDL was established. The MDL combines lawsuits from across the country, which will be tried before the U.S. District Court of the Northern District for Illinois.

The Jere Beasley Report explained that drugmakers must also answer for their aggressive marketing efforts and their attempts to downplay the risks of heart attacks and strokes associated with the drugs.

Slick marketing campaigns have fueled a sharp climb in “Low T” drug sales. The now $2 billion industry increased more than five-fold from 2000 to 2011, Beasley Allen reported. One pharmaceutical company, AbbVie, paid more than $20 million to 191,555 doctors from August 2013 to December 2015 to promote its testosterone replacement drug, AndroGel.

The drugs appear under other brand names including Axiron, Bio-T-Gel, Delatestryl, Depo-Testosterone, Fortesta, Striant, Testim and Testopel.

* * *

If you or a loved one has suffered a heart attack or stroke while taking testosterone supplements, or if someone you love has died, you can contact Matthew Teague, a lawyer in the firm’s Personal Injury and Product Liability Section at 800-898-2034 or by email at Matthew.Teague@beasleyallen.com. More information about testosterone replacement drugs or replacement therapy can be found at lowt-lawyer.com.

Sources:
Righting Injustice
Beasley Allen
Beasley Allen
Righting Injustice
Jere Beasley Report (January 2017)
Beasley Allen



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Testosterone treatment increases risk of heart attack, stroke, death

Legal woes, health risks lead to shrinking...

The prescription-only drugs were first approved by the Food and Drug Administration (FDA) as treatment...
Testosterone treatment increases risk of heart attack, stroke, death

Jury awards $140 million to Plaintiff in testosterone...

A jury in Illinois federal court awarded Plaintiff Jeffrey Konrad $140 million in litigation involving...
Testosterone treatment increases risk of heart attack, stroke, death

New trial for testosterone litigation starts next week

Plaintiffs maintain that despite not being designed to treat symptoms of age-related testosterone...
Testosterone treatment increases risk of heart attack, stroke, death

Jury hits testosterone therapy maker AbbVie with $150...

The jury found that AbbVie fraudulently marketed AndroGel by creating a condition dubbed “Low T,”...
Testosterone treatment increases risk of heart attack, stroke, death

First bellwether trial in testosterone litigation...

The first trial in multidistrict litigation (MDL) involving testosterone replacement therapy (TRT) began...
Testosterone treatment increases risk of heart attack, stroke, death

Lawsuits target drug makers over testosterone side...

Testosterone drugs heavily advertised by pharmaceutical companies for men who have “Low T,” or low...

Highly recommended

I would highly recommend this law firm to handle any of your legal needs.

—Sandy